Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...

Man City struggled throughout last season. New data suggests they are improving and should enjoy success in the final third against Liverpool.

According to SMM's assessment, China's antimony ingot production (including antimony ingots, converted crude antimony, antimony cathode, etc.) in October 2025 increased by approximately 22.86% MoM ...

Strong execution and operational excellence drove improved performanceYear-over-year comparison (third quarter of 2025 versus third quarter of 2024):Sales increased 2% to $10.5 billion, supported by a ...

Research and Development (R&D) Expenses: R&D expenses were $10.7 million for the third quarter of 2025, compared to $14.1 million for the same period in 2024. General and Administrative (G&A) Expenses ...

The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Thank you for standing by. At this time, I would like to welcome ...

UVI Model: Underwriting Variable Importance model, a proprietary predictive analytics framework used to enhance pricing, risk ...

AdvanSix Inc. (NYSE: ASIX) Q3 2025 Earnings Call Transcript November 7, 2025 AdvanSix Inc. misses on earnings expectations.

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerabilit ...

Q3 2025 Earnings Call November 6, 2025 5:00 PM ESTCompany ParticipantsJason Dammeyer - Director of SEC Reporting ...

It's one of medicine's biggest mysteries — why sometimes our immune system attacks our own bodies. Autoimmune diseases affect ...